Jun-Ping Liu

List of Publications by Year
in descending order

142 papers	7,534 citations	50276 46 h-index	60623 81 g-index
145 all docs	145 docs citations	145 times ranked	10038 citing authors

#	Article	IF	Citations
1	Molecular Mechanisms of Alveolar Epithelial Stem Cell Senescence and Senescence-Associated Differentiation Disorders in Pulmonary Fibrosis. Cells, 2022, 11, 877.	4.1	13
2	Pyrroline-5-carboxylate synthase senses cellular stress and modulates metabolism by regulating mitochondrial respiration. Cell Death and Differentiation, 2021, 28, 303-319.	11.2	14
3	Sir4 Deficiency Reverses Cell Senescence by Sub-Telomere Recombination. Cells, 2021, 10, 778.	4.1	4
4	Mechanisms of cancer stem cell senescence: Current understanding and future perspectives. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 1185-1202.	1.9	16
5	Regulation of lipid homeostasis by the TBC protein dTBC1D22 via modulation of the small GTPase Rab40 to facilitate lipophagy. Cell Reports, 2021, 36, 109541.	6.4	6
6	Identification of peptidomimetic telomere dysfunction inhibitor (TELODIN) through telomere dysfunction-induced foci (TIF) assay. STAR Protocols, 2021, 2, 100620.	1.2	4
7	Pulmonary Alveolar Stem Cell Senescence, Apoptosis, and Differentiation by p53-Dependent and -Independent Mechanisms in Telomerase-Deficient Mice. Cells, 2021, 10, 2892.	4.1	5
8	Combined 3D-QSAR, molecular docking and molecular dynamics study on the benzimidazole inhibitors targeting HCV NS5B polymerase. Journal of Biomolecular Structure and Dynamics, 2020, 38, 1071-1082.	3.5	14
9	Identification of new hypoxiaâ€regulated epithelialâ€mesenchymal transition marker genes labeled by H3K4 acetylation. Genes Chromosomes and Cancer, 2020, 59, 73-83.	2.8	19
10	Chchd2 regulates mitochondrial morphology by modulating the levels of Opa1. Cell Death and Differentiation, 2020, 27, 2014-2029.	11.2	33
11	Role of telomerase in the tumour microenvironment. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 357-364.	1.9	17
12	Molecular insight into the selective binding between human telomere Gâ€quadruplex and a negatively charged stabilizer. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 892-902.	1.9	7
13	FBW7 Mediates Senescence and Pulmonary Fibrosis through Telomere Uncapping. Cell Metabolism, 2020, 32, 860-877.e9.	16.2	51
14	Antimicrobial activity and mechanism of peptide CM4 againstPseudomonas aeruginosa. Food and Function, 2020, 11, 7245-7254.	4.6	11
15	Epidemiological and clinical features of pediatric COVID-19. BMC Medicine, 2020, 18, 250.	5.5	88
16	Simultaneous visualisation of the complete sets of telomeres from the MmeI generated terminal restriction fragments in yeasts. Yeast, 2020, 37, 585-595.	1.7	1
17	Insight Derived from Molecular Dynamics Simulation into the Selectivity Mechanism Targeting c-MYC G-Quadruplex. Journal of Physical Chemistry B, 2020, 124, 9773-9784.	2.6	7
18	Covidâ€19: From structure to therapeutic targeting in studying approved drugs and local DNA vaccination. Clinical and Experimental Pharmacology and Physiology, 2020, 47, 1771-1773.	1.9	0

#	Article	IF	Citations
19	A method for efficient quantitative analysis of genomic subtelomere Yâ€² element abundance in yeasts. Yeast, 2020, 37, 373-388.	1.7	3
20	Miga-mediated endoplasmic reticulumâ€“mitochondria contact sites regulate neuronal homeostasis. ELife, 2020, 9, .	6.0	31
21	Effects of cation charges on the binding of stabilizers with human telomere and TERRA G-quadruplexes. Journal of Biomolecular Structure and Dynamics, 2019, 37, 1908-1921.	3.5	8
22	Roles of Telomere Biology in Cell Senescence, Replicative and Chronological Ageing. Cells, 2019, 8, 54.	4.1	109
23	Pharmacogenomics guidelines: Current status and future development. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 689-693.	1.9	19
24	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PDâ€1/PDâ€L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 105-115.	1.9	16
25	CFP1 coordinates histone H3 lysine-4 trimethylation and meiotic cell cycle progression in mouse oocytes. Nature Communications, 2018, 9, 3477.	12.8	51
26	MAPK cascade couples maternal mRNA translation and degradation to meiotic cell cycle progression in mouse oocyte. Development (Cambridge), 2017, 144, 452-463.	2.5	78
27	Effects of the central potassium ions on the G-quadruplex and stabilizer binding. Journal of Molecular Graphics and Modelling, 2017, 72, 168-177.	2.4	27
28	Impulse control disorder, lysosomal malfunction and <scp>ATP</scp>13A2 insufficiency in Parkinsonism. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 172-179.	1.9	4
29	Telomere Damage Response and Low-Grade Inflammation. Advances in Experimental Medicine and Biology, 2017, 1024, 213-224.	1.6	7
30	CFP1 Regulates Histone H3K4 Trimethylation and Developmental Potential in Mouse Oocytes. Cell Reports, 2017, 20, 1161-1172.	6.4	89
31	The polycystic ovary syndrome-associated gene Yap1 is regulated by gonadotropins and sex steroid hormones in hyperandrogenism-induced oligo-ovulation in mouse. Molecular Human Reproduction, 2017, 23, 698-707.	2.8	41
32	Maternal DCAF2 is crucial for maintenance of genome stability during the first cell cycle in mice. Journal of Cell Science, 2017, 130, 3297-3307.	2.0	16
33	Aging mechanisms and intervention targets. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 3-8.	1.9	5
34	Identification of a cyclodextrin inclusion complex of antimicrobial peptide CM4 and its antimicrobial activity. Food Chemistry, 2017, 221, 296-301.	8.2	20
35	TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence. Protein and Cell, 2017, 8, 39-54.	11.0	31
36	Novel strategies for molecular targeting to cancer. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 287-289.	1.9	6

#	Article	IF	Citations
37	hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor. Nucleic Acids Research, 2016, 44, 8693-8703.	14.5	87
38	<scp>PI</scp>3K/Akt/<scp>mTOR</scp> pathway dual inhibitor <scp>BEZ</scp>235 suppresses the stemness of colon cancer stem cells. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1317-1326.	1.9	76
39	Stressed <scp>SIRT</scp>7: facing a crossroad of senescence and immortality. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 567-569.	1.9	7
40	Characterization of potassium binding with human telomeres. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 902-909.	1.9	7
41	Telomerase Deficiency Causes Alveolar Stem Cell Senescence-associated Low-grade Inflammation in Lungs. Journal of Biological Chemistry, 2015, 290, 30813-30829.	3.4	72
42	BTB-ZF transcriptional regulator PLZF modifies chromatin to restrain inflammatory signaling programs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1535-1540.	7.1	54
43	The acetyltransferase HAT1 moderates the NF-ÎºB response by regulating the transcription factor PLZF. Nature Communications, 2015, 6, 6795.	12.8	62
44	Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways. Nature Communications, 2015, 6, 6808.	12.8	53
45	Current aging research in China. Protein and Cell, 2015, 6, 314-321.	11.0	31
46	Molecular dynamics and principal components of potassium binding with human telomeric intra-molecular G-quadruplex. Protein and Cell, 2015, 6, 423-433.	11.0	14
47	Identification of interferon-Î³-inducible-lysosomal thiol reductase (GILT) gene in goldfish (Carassius) Tj ETQq1 1 0.784314 rgBT /Overlock	3.6	8
48	Î±Bâ€Crystallin R120G variant causes cardiac arrhythmias and alterations in the expression of Ca²⁺â€handling proteins and endoplasmic reticulum stress in mice. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 589-599.	1.9	19
49	Increased polymerase I and transcript release factor (Cavinâ€1) expression attenuates plateletâ€derived growth factor receptor signalling in senescent human fibroblasts. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 169-173.	1.9	13
50	Cellular senescence occurred widespread to multiple selective sites in the fetal tissues and organs of mice. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 965-975.	1.9	12
51	Molecular mechanisms of ageing and related diseases. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 445-458.	1.9	40
52	Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Letters, 2014, 344, 239-259.	7.2	131
53	CBP-CITED4 is required for luteinizing hormone-triggered target gene expression during ovulation. Molecular Human Reproduction, 2014, 20, 850-860.	2.8	26
54	Distinct Pathways of ERK1/2 Activation by Hydroxy-Carboxylic Acid Receptor-1. PLoS ONE, 2014, 9, e93041.	2.5	27

#	Article	IF	Citations
55	A turning point: Focusing on translational medicine. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 485-488.	1.9	4
56	ATF3 Suppresses Metastasis of Bladder Cancer by Regulating Gelsolin-Mediated Remodeling of the Actin Cytoskeleton. Cancer Research, 2013, 73, 3625-3637.	0.9	114
57	Serine/threonineâ€protein phosphatase 2A physically interacts with human telomerase reverse transcriptase hTERT and regulates its subcellular distribution. Journal of Cellular Biochemistry, 2013, 114, 409-417.	2.6	13
58	Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging. Journal of Infectious Diseases, 2013, 207, 1157-1165.	4.0	113
59	Osteopontin promotes inflammation in patients with acute coronary syndrome through its activity on <scp>IL</scp>â€17 producing cells. European Journal of Immunology, 2012, 42, 2803-2814.	2.9	22
60	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) induces cancer cell senescence by interacting with telomerase RNA component. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13308-13313.	7.1	60
61	GAPDH: A common enzyme with uncommon functions. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 674-679.	1.9	207
62	Introduction: Understanding the signalling mechanisms in molecular physiology and diseases. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 658-660.	1.9	0
63	Suppression of the notch signaling pathway by Î³-secretase inhibitor GSI inhibits human nasopharyngeal carcinoma cell proliferation. Cancer Letters, 2011, 306, 76-84.	7.2	20
64	Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica, 2011, 41, 259-280.	1.1	50
65	Telomere protein complexes and interactions with telomerase in telomere maintenance. Frontiers in Bioscience - Landmark, 2011, 16, 187.	3.0	33
66	Estrogen deficiency reversibly induces telomere shortening in mouse granulosa cells and ovarian aging in vivo. Protein and Cell, 2011, 2, 333-346.	11.0	62
67	Molecular regulation of telomerase activity in aging. Protein and Cell, 2011, 2, 726-738.	11.0	50
68	Chromosomal and telomeric reprogramming following ES-somatic cell fusion. Chromosoma, 2010, 119, 167-176.	2.2	17
69	Telomerase in cancer immunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 35-42.	7.4	38
70	Phenotype prediction of deleterious nonsynonymous single nucleotide polymorphisms in human alcohol metabolism-related genes: a bioinformatics study. Alcohol, 2010, 44, 425-438.	1.7	7
71	Alternative lengthening of telomeres in hTERTâ€inhibited laryngeal cancer cells. Cancer Science, 2010, 101, 1769-1776.	3.9	20
72	Niemannâ€“Pick disease Type C: From molecule to clinic. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 132-140.	1.9	38

#	Article	IF	Citations
73	Ets2 transcription factor, telomerase activity and breast cancer. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 83-87.	1.9	30
74	Oestrogen, telomerase, ovarian ageing and cancer. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 78-82.	1.9	24
75	Strategies of treating cancer by cytokine regulation of chromosome end remodelling. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 88-92.	1.9	7
76	2009 Nobel Prize in physiology and medicine awarded for an enzyme in cancer. Clinical and Experimental Pharmacology and Physiology, 2010, 37, 75-77.	1.9	1
77	Comparison of reprogramming ability of mouse ES and iPS cells measured by somatic cell fusion. International Journal of Developmental Biology, 2010, 54, 1723-1728.	0.6	6
78	Herbal Interactions with Anticancer Drugs: Mechanistic and Clinical Considerations. Current Medicinal Chemistry, 2010, 17, 1635-1678.	2.4	76
79	Modulators of Multidrug Resistance Proteins in the Management of Anticancer and Antimicrobial Drug Resistance and the Treatment of Inflammatory Diseases. Current Topics in Medicinal Chemistry, 2010, 10, 1732-1756.	2.1	26
80	Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews, 2010, 42, 268-354.	3.6	220
81	Telomerase in the ovary. Reproduction, 2010, 140, 215-222.	2.6	56
82	TGF-Î² induces telomerase-dependent pancreatic tumor cell cycle arrest. Molecular and Cellular Endocrinology, 2010, 320, 97-105.	3.2	20
83	Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Molecular and Cellular Neurosciences, 2010, 43, 33-42.	2.2	177
84	Regulation of telomerase activity by apparently opposing elements. Ageing Research Reviews, 2010, 9, 245-256.	10.9	43
85	Substrate Specificity, Inhibitors and Regulation of Human Cytochrome P450 2D6 and Implications in Drug Development. Current Medicinal Chemistry, 2009, 16, 2661-2805.	2.4	64
86	GSK3Î² modulates PACAP-induced neuritogenesis in PC12 cells by acting downstream of Rap1 in a caveolae-dependent manner. Cellular Signalling, 2009, 21, 237-245.	3.6	20
87	Prediction of Deleterious Non-synonymous Single-Nucleotide Polymorphisms of Human Uridine Diphosphate Glucuronosyltransferase Genes. AAPS Journal, 2009, 11, 469-80.	4.4	21
88	Anti-angiogenesis and anti-tumor effects of AdNT4-anginex. Cancer Letters, 2009, 285, 218-224.	7.2	17
89	Activin inhibits telomerase activity in cancer. Biochemical and Biophysical Research Communications, 2009, 389, 668-672.	2.1	11
90	New functions of cholesterol binding proteins. Molecular and Cellular Endocrinology, 2009, 303, 1-6.	3.2	17

#	Article	IF	Citations
91	Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews, 2009, 41, 89-295.	3.6	671
92	Human CYP2C8: Structure, Substrate Specificity, Inhibitor Selectivity, Inducers and Polymorphisms. Current Drug Metabolism, 2009, 10, 1009-1047.	1.2	80
93	Establishment, Immortalisation and Characterisation of Pteropid Bat Cell Lines. PLoS ONE, 2009, 4, e8266.	2.5	143
94	TGFâ€Î² superfamily typeâ€II receptor regulation of telomerase and telomeres in human breast cancer cells. FASEB Journal, 2009, 23, 485.1.	0.5	0
95	Estrogen deficiency leads to telomerase inhibition, telomere shortening and reduced cell proliferation in the adrenal gland of mice. Cell Research, 2008, 18, 1141-1150.	12.0	65
96	The C-terminus of PRK2/PKNÎ³ is required for optimal activation by RhoA in a GTP-dependent manner. Archives of Biochemistry and Biophysics, 2008, 479, 170-178.	3.0	10
97	Ets2 Maintains hTERT Gene Expression and Breast Cancer Cell Proliferation by Interacting with c-Myc. Journal of Biological Chemistry, 2008, 283, 23567-23580.	3.4	134
98	Application of combination of short hairpin RNA segments for silencing VEGF, TERT, and Bcl-xl expression in laryngeal squamous carcinoma. Cancer Biology and Therapy, 2008, 7, 896-901.	3.4	15
99	Bone Morphogenetic Protein-7 Inhibits Telomerase Activity, Telomere Maintenance, and Cervical Tumor Growth. Cancer Research, 2008, 68, 9157-9166.	0.9	38
100	Mechanisms of Action of TGFâ€Î² in Cancer. Annals of the New York Academy of Sciences, 2007, 1114, 56-68.	3.8	35
101	Transcriptional Regulation of Telomerase Activity. Annals of the New York Academy of Sciences, 2007, 1114, 36-47.	3.8	80
102	Potential Roles for Estrogen Regulation of Telomerase Activity in Aging. Annals of the New York Academy of Sciences, 2007, 1114, 48-55.	3.8	41
103	Inhibition of Telomerase by Targeting MAP Kinase Signaling. Methods in Molecular Biology, 2007, 405, 147-165.	0.9	8
104	Uses of Telomerase Peptides in Anti-Tumor Immune Therapy. Methods in Molecular Biology, 2007, 405, 61-86.	0.9	7
105	Effects of 17Î²-estradiol on growth and apoptosis in human vascular endothelial cells: Influence of mechanical strain and tumor necrosis factor-Î±. Steroids, 2006, 71, 799-808.	1.8	37
106	TGF-Î² and cancer: Is Smad3 a repressor of hTERT gene?. Cell Research, 2006, 16, 169-173.	12.0	40
107	Mechanisms of cell immortalization mediated by EB viral activation of telomerase in nasopharyngeal carcinoma. Cell Research, 2006, 16, 809-817.	12.0	35
108	Transforming Growth Factor Î² Suppresses Human Telomerase Reverse Transcriptase (hTERT) by Smad3 Interactions with c-Myc and the hTERT Gene. Journal of Biological Chemistry, 2006, 281, 25588-25600.	3.4	112

#	Article	IF	Citations
109	Telomerase down-regulation does not mediate PC12 pheochromocytoma cell differentiation induced by NGF, but requires MAP kinase signalling. Journal of Neurochemistry, 2005, 95, 891-901.	3.9	25
110	Hormones and growth factors regulate telomerase activity in ageing and cancer. Molecular and Cellular Endocrinology, 2005, 240, 11-22.	3.2	106
111	Dehydroepiandrosterone Inhibits Human Vascular Smooth Muscle Cell Proliferation Independent of ARs and ERs. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 176-181.	3.6	129
112	Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension ¹. FASEB Journal, 2002, 16, 96-98.	0.5	61
113	High glucose abolishes the antiproliferative effect of 17Î²-estradiol in human vascular smooth muscle cells. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E746-E751.	3.5	16
114	TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene, 2002, 21, 3130-3138.	5.9	189
115	Signaling on telomerase: a master switch in cell aging and immortalization. Biogerontology, 2002, 3, 107-116.	3.9	15
116	Molecular mechanisms regulating telomerase activity. Advances in Cell Aging and Gerontology, 2001, 8, 33-59.	0.1	7
117	Dynamin II Regulates Hormone Secretion in Neuroendocrine Cells. Journal of Biological Chemistry, 2001, 276, 4251-4260.	3.4	35
118	Telomerase: Not Just Black and White, but Shades of Gray. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 2000, 3, 129-135.	1.6	15
119	Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB Journal, 1999, 13, 2091-2104.	0.5	240
120	Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro. Oncogene, 1999, 18, 6785-6794.	5.9	80
121	Androgen stimulates mitogen-activated protein kinase in human breast cancer cells. Molecular and Cellular Endocrinology, 1999, 152, 199-206.	3.2	57
122	Growth factors and extracellular signal-regulated kinase in vascular smooth muscle cells of normotensive and spontaneously hypertensive rats. Journal of Hypertension, 1999, 17, 1535-1541.	0.5	14
123	Differential regulation of MAP kinase activity by corticotropin-releasing hormone in normal and neoplastic corticotropes. International Journal of Biochemistry and Cell Biology, 1998, 30, 1389-1401.	2.8	26
124	Telomerase Is Controlled by Protein Kinase CÎ± in Human Breast Cancer Cells. Journal of Biological Chemistry, 1998, 273, 33436-33442.	3.4	188
125	Aldosterone Rapidly Represses Protein Kinase C Activity in Neonatal Rat Cardiomyocytes in Vitro. Endocrinology, 1997, 138, 3410-3416.	2.8	52
126	Protein Phosphatase 2A Inhibits Nuclear Telomerase Activity in Human Breast Cancer Cells. Journal of Biological Chemistry, 1997, 272, 16729-16732.	3.4	174

#	Article	IF	Citations
127	Molecular interactions between dynamin and G-protein Î²Î³-subunits in neuroendocrine cells. Molecular and Cellular Endocrinology, 1997, 132, 61-71.	3.2	20
128	PROTEIN PHOSPHORYLATION EVENTS IN EXOCYTOSIS AND ENDOCYTOSIS.. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 611-618.	1.9	24
129	Protein kinase C and its substrates. Molecular and Cellular Endocrinology, 1996, 116, 1-29.	3.2	228
130	Multiple Substrates for cGMP-Dependent Protein Kinase from Bovine Aortic Smooth Muscle: Purification of P132. Journal of Vascular Research, 1996, 33, 99-110.	1.4	10
131	Calcium Binds Dynamin I and Inhibits Its GTPase Activity. Journal of Neurochemistry, 1996, 66, 2074-2081.	3.9	37
132	Dynamin and Endocytosis*. Endocrine Reviews, 1995, 16, 590-607.	20.1	61
133	Calcineurin inhibition of dynamin I GTPase activity coupled to nerve terminal depolarization. Science, 1994, 265, 970-973.	12.6	209
134	Phosphorylation of dynamin I and synaptic-vesicle recycling. Trends in Neurosciences, 1994, 17, 348-353.	8.6	120
135	Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion. Molecular and Cellular Endocrinology, 1994, 101, 247-256.	3.2	18
136	Corticotropin-release inhibitory factor. Trends in Endocrinology and Metabolism, 1994, 5, 272-283.	7.1	11
137	A comparative study of the role of adenylate cyclase in the release of adrenocorticotropin from the ovine and rat anterior pituitary. Molecular and Cellular Endocrinology, 1994, 101, 173-181.	3.2	7
138	Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophysial-portal circulation of the conscious sheep. II. The central noradrenergic and neuropeptide Y pathways cause immediate and prolonged hypothalamic-pituitary-adrenal activation. Potential involvement in the pseudo-Cushing's syndrome of endogenous depression and anorexia nervosa.. Journal of Clinical Investigation, 1994, 93, 1439-1450.	8.2	73
139	Dynamin GTPase regulated by protein kinase C phosphorylation in nerve terminals. Nature, 1993, 365, 163-166.	27.8	284
140	Evidence that the stimulation by arginine vasopressin of the release of adrenocorticotropin from the ovine anterior pituitary involves the activation of protein kinase C. Molecular and Cellular Endocrinology, 1992, 87, 35-47.	3.2	21
141	Evidence That the Central Noradrenergic and Adrenergic Pathways Activate the Hypothalamic-Pituitary-Adrenal Axis in the Sheep*. Endocrinology, 1991, 129, 200-209.	2.8	32
142	Studies of the Regulation of the Hypothalamic-Pituitary-Adrenal Axis in Sheep with Hypothalamic-Pituitary Disconnection. II. Evidence forin VivoUltradian Hypersecretion of Proopiomelanocortin Peptides by the Isolated Anterior and Intermediate Pituitary*. Endocrinology, 1990, 127, 1956-1966.	2.8	61